These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 17590215)

  • 41. Double-blind comparison of escitalopram and duloxetine in the acute treatment of major depressive disorder.
    Khan A; Bose A; Alexopoulos GS; Gommoll C; Li D; Gandhi C
    Clin Drug Investig; 2007; 27(7):481-92. PubMed ID: 17563128
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy, safety and tolerability of duloxetine 60 mg once daily in major depression.
    Cowen PJ; Ogilvie AD; Gama J
    Curr Med Res Opin; 2005 Mar; 21(3):345-56. PubMed ID: 15811202
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical impact of duloxetine treatment on sleep in patients with major depressive disorder.
    Brecht S; Kajdasz D; Ball S; Thase ME
    Int Clin Psychopharmacol; 2008 Nov; 23(6):317-24. PubMed ID: 18854719
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Escitalopram and duloxetine in major depressive disorder: a pharmacoeconomic comparison using UK cost data.
    Wade AG; Fernández JL; François C; Hansen K; Danchenko N; Despiegel N
    Pharmacoeconomics; 2008; 26(11):969-81. PubMed ID: 18850765
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Changes in sexual functioning associated with duloxetine, escitalopram, and placebo in the treatment of patients with major depressive disorder.
    Clayton A; Kornstein S; Prakash A; Mallinckrodt C; Wohlreich M
    J Sex Med; 2007 Jul; 4(4 Pt 1):917-29. PubMed ID: 17627739
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Switching to duloxetine in selective serotonin reuptake inhibitor non- and partial-responders: effects on painful physical symptoms of depression.
    Perahia DG; Quail D; Desaiah D; Montejo AL; Schatzberg AF
    J Psychiatr Res; 2009 Feb; 43(5):512-8. PubMed ID: 18707693
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Safety and tolerability of duloxetine at 60 mg once daily in elderly patients with major depressive disorder.
    Raskin J; Wiltse CG; Dinkel JJ; Walker DJ; Desaiah D; Katona C
    J Clin Psychopharmacol; 2008 Feb; 28(1):32-8. PubMed ID: 18204338
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A randomized, double-blind study of increasing or maintaining duloxetine dose in patients without remission of major depressive disorder after initial duloxetine therapy.
    Kornstein SG; Dunner DL; Meyers AL; Whitmyer VG; Mallinckrodt CH; Wohlreich MM; Detke MJ; Hollandbeck MS; Greist JH
    J Clin Psychiatry; 2008 Sep; 69(9):1383-92. PubMed ID: 19193339
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder.
    Arnold LM; Rosen A; Pritchett YL; D'Souza DN; Goldstein DJ; Iyengar S; Wernicke JF
    Pain; 2005 Dec; 119(1-3):5-15. PubMed ID: 16298061
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder.
    Mahableshwarkar AR; Jacobsen PL; Chen Y
    Curr Med Res Opin; 2013 Mar; 29(3):217-26. PubMed ID: 23252878
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Safety and tolerability of duloxetine in elderly patients with major depressive disorder: a pooled analysis of two placebo-controlled studies.
    Oakes TM; Katona C; Liu P; Robinson M; Raskin J; Greist JH
    Int Clin Psychopharmacol; 2013 Jan; 28(1):1-11. PubMed ID: 23138680
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Early vs. conventional switching of antidepressants in patients with MDD and moderate to severe pain: a double-blind randomized study.
    Romera I; Pérez V; Menchón JM; Schacht A; Papen R; Neuhauser D; Abbar M; Picard H; Gilaberte I
    J Affect Disord; 2012 Dec; 143(1-3):47-55. PubMed ID: 22858211
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine.
    Goldstein DJ; Lu Y; Detke MJ; Wiltse C; Mallinckrodt C; Demitrack MA
    J Clin Psychopharmacol; 2004 Aug; 24(4):389-99. PubMed ID: 15232330
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial.
    Rynn M; Russell J; Erickson J; Detke MJ; Ball S; Dinkel J; Rickels K; Raskin J
    Depress Anxiety; 2008; 25(3):182-9. PubMed ID: 17311303
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Sexual functioning assessed in 4 double-blind placebo- and paroxetine-controlled trials of duloxetine for major depressive disorder.
    Delgado PL; Brannan SK; Mallinckrodt CH; Tran PV; McNamara RK; Wang F; Watkin JG; Detke MJ
    J Clin Psychiatry; 2005 Jun; 66(6):686-92. PubMed ID: 15960560
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Extended release quetiapine fumarate monotherapy in major depressive disorder: a placebo- and duloxetine-controlled study.
    Cutler AJ; Montgomery SA; Feifel D; Lazarus A; Aström M; Brecher M
    J Clin Psychiatry; 2009 Apr; 70(4):526-39. PubMed ID: 19358790
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Duloxetine in the treatment of elderly people with major depressive disorder.
    Del Casale A; Girardi P; Brugnoli R; Sani G; Di Pietro S; Brugnoli C; Caccia F; Angeletti G; Serata D; Rapinesi C; Tatarelli R; Kotzalidis GD
    Riv Psichiatr; 2012; 47(6):479-88. PubMed ID: 23160108
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A non-comparative assessment of tolerability and efficacy of duloxetine in the treatment of depressed patients with Parkinson's disease.
    Bonuccelli U; Meco G; Fabbrini G; Tessitore A; Pierantozzi M; Stocchi F; Ceravolo R; Caltagirone C; Silvestrini M; Morgante F; Ruggieri S; Avanzino L; Guadagna M; Dell'Agnello G; Rossi A; Spezia R; Mancini M
    Expert Opin Pharmacother; 2012 Nov; 13(16):2269-80. PubMed ID: 23067321
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Duloxetine in the treatment of major depressive disorder: comparisons of safety and tolerability in male and female patients.
    Stewart DE; Wohlreich MM; Mallinckrodt CH; Watkin JG; Kornstein SG
    J Affect Disord; 2006 Aug; 94(1-3):183-9. PubMed ID: 16780958
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Time course of improvement of different symptom clusters in patients with major depression and pain treated with duloxetine or placebo.
    Demyttenaere K; Desaiah D; Petit C; Croenlein J; Brecht S
    Curr Med Res Opin; 2012 Jan; 28(1):41-8. PubMed ID: 22126422
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.